Efficacy and Safety of Zotarolimus-eluting Stents and Sirolimus-eluting Stents in Treatment of Coronary Heart Disease: a Meta-analysis

DONG Shi-jia; XIA Hao

doi:10.3969/j.issn.1002-3429.2017.08.021

Abstract：Objective To assess the efficacy and safety of Zotarolimus-eluting stent (ZES) and Sirolimus-eluting stent (SES) in treatment of coronary heart disease (CHD).Methods Related papers about ZES and SES were retrieved in CJFD, CBM, VIP, WanFang databases from establishment to March 2015, PubMed database from 1990 to March 2015 and Cochrane Library in March 2015 for randomized controlled trials (RCTs).The papers were screened and extracted by internalizing and evacuating, and the qualities of papers were evaluated by using Jadad reforming scale, and then meta analysis was performed by using Rev Man 5.2 software.Results A total of 11 papers (7171 cases) were included in this study.Meta-analysis result showed that there were no significant differences in incidence rate of cardiac death [RR=0.71, 95%CI(0.42, 1.20), P=0.20], major adverse cardiovascular events [RR=1.20, 95%CI(0.87, 1.65), P=0.28] and definite or probable incidence rate of stent thrombosis [RR=0.80, 95%CI(0.37, 1.75), P=0.58] between ZES and SES groups.In ZES group, revascularization rate of target lesion [RR=2.02, 95%CI(1.25, 3.26), P=0.004] and revascularization rate of target vessel [RR=1.62, 95%CI(1.05, 2.52), P=0.03] were significantly higher, while incidence rate of myocardial infarction (MI) events [RR=0.77, 95%CI (0.60, 0.99), P=0.04] was significantly lower than those in SES group.Conclusion In CHD treatment with stent implantation, ZES can significantly reduce incidence rate of MI events, increase revascularization rates of target lesion and target vessel compared with those by SES, but ZES has similar to SES in incidence rates of cardiac death, major adverse cardiovascular events and definite or probable incidence rate of stent thrombosis.